Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease
- 2 October 2000
- journal article
- review article
- Published by Springer Nature in Diabetologia
- Vol. 43 (10) , 1205-1223
- https://doi.org/10.1007/s001250051515
Abstract
The development of diabetic nephropathy in patients with Type I (insulin-dependent) and Type II (non-insulin-dependent) diabetes mellitus is still a huge clinical problem associated with increased morbidity and mortality. The mechanisms underlying the development of diabetic kidney disease are extremely complex and yet not completely understood. Among many potential pathogenic mechanisms responsible for the development of diabetic kidney disease, various growth factors have been suggested to be important players. In particular, growth hormone (GH)/insulin-like growth factors (IGFs), transforming growth factor β (TGF-β), vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) have measurable effects on the development of experimental diabetic kidney disease through complex intra-renal systems. Recent findings that these growth factors might initiate the early diabetic renal changes have provided insight into processes that might be relevant for future development of new drugs useful in the treatment of diabetic kidney disease. As will appear from the present review, enhanced understanding of the cellular mechanisms responsible for the development of diabetic kidney disease has already allowed the design of specific antagonists of pathophysiologically increased growth factors. Recent studies have shown that treating experimental diabetic models with such antagonists is followed by renoprotection. [Diabetologia (2000) 43: 1205–1223]Keywords
This publication has 46 references indexed in Scilit:
- Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC β inhibitor in diabetic db/db mice, a rodent model for type 2 diabetesThe FASEB Journal, 2000
- Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptorNature Medicine, 1999
- Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox.Diabetes, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Renal origin of rat urinary epidermal growth factorRegulatory Peptides, 1984
- Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites FluidScience, 1983
- MICROALBUMINURIA AS A PREDICTOR OF CLINICAL NEPHROPATHY IN INSULIN-DEPENDENT DIABETES MELLITUSThe Lancet, 1982
- Growth Hormone Secretory Dynamics in Streptozotocin Diabetes: Evidence of a Role for Endogenous Circulating Somatostatin*Endocrinology, 1981
- Prognosis of diabetics with diabetes onset before the age of thirtyoneDiabetologia, 1978
- THE PRODUCTION OF PERMANENT DIABETES BY HIGHLY PURIFIED GROWTH HORMONEEndocrinology, 1950